rimexolone - Profile

What are the generic sources for rimexolone and what is the scope of patent protection?

Rimexolone is the generic ingredient in one branded drug marketed by Harrow Eye and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for rimexolone

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for rimexolone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harrow Eye	VEXOL	rimexolone	SUSPENSION/DROPS;OPHTHALMIC	020474-001	Dec 30, 1994		DISCN	No	No

Expired US Patents for rimexolone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Harrow Eye	VEXOL	rimexolone	SUSPENSION/DROPS;OPHTHALMIC	020474-001	Dec 30, 1994

Rimexolone: Patent Landscape and Commercialization Assessment

Last updated: February 18, 2026

Rimexolone, a topical corticosteroid, has demonstrated efficacy in treating ocular inflammation, primarily uveitis and post-operative inflammation. Its market potential is directly tied to its patent exclusivity, clinical utility, and competitive landscape. This analysis assesses the current patent status, key clinical findings, and competitive positioning of rimexolone to inform investment and R&D decisions.

What is the Current Patent Status of Rimexolone?

The foundational patent for rimexolone, originally held by Syntex, expired in the United States in 2007 [1]. This early expiration has allowed for the entry of generic formulations. Subsequent patents often relate to specific formulations, manufacturing processes, or novel delivery methods, rather than the core compound itself. Identifying and assessing these secondary patents is crucial for understanding any remaining market exclusivity or opportunities for innovation.

Patent Type	Expiration Date (US)	Key Innovation	Status
Compound Patent (Original)	2007	Active pharmaceutical ingredient (API)	Expired
Formulation Patents	Varies (e.g., 2010s)	Ophthalmic emulsion, sustained-release formulations	Expired/Nearing Expiry
Manufacturing Process Patents	Varies	Novel synthesis routes, purification techniques	Expired/Nearing Expiry

The absence of a strong, unexpired patent for the API itself signifies that the primary intellectual property protection has lapsed. This limits the potential for new market entrants to rely on patent barriers. Any future differentiation for rimexolone-based products will likely depend on superior formulation technology, clinical trial data demonstrating specific advantages, or unique marketing strategies.

What is the Clinical Efficacy and Safety Profile of Rimexolone?

Rimexolone is a potent anti-inflammatory agent that functions by binding to glucocorticoid receptors, thereby inhibiting the synthesis of inflammatory mediators such as prostaglandins and leukotrienes [2]. Its clinical application is concentrated in ophthalmology, where it is used to manage conditions involving inflammation of the eye.

Key Indications and Efficacy Data

• Uveitis: Clinical trials have shown rimexolone to be effective in reducing inflammation in patients with non-infectious anterior uveitis. For instance, a study by Tsuboi et al. (1996) reported a significant reduction in anterior chamber cells and flare in patients treated with rimexolone ophthalmic suspension compared to placebo [3]. The typical dosing regimen involves instilling one drop into the affected eye(s) four times daily.
• Post-operative Inflammation: Following ophthalmic surgery, such as cataract extraction, rimexolone is used to suppress inflammation and prevent complications. Studies have demonstrated its ability to control post-surgical inflammation, leading to faster visual recovery and improved patient comfort [4].

Safety Profile Considerations

• Intraocular Pressure (IOP) Elevation: Like other topical corticosteroids, rimexolone carries a risk of elevating intraocular pressure. This is a common side effect that requires monitoring, particularly in patients with a history of glaucoma or ocular hypertension. Studies indicate that approximately 20-30% of patients treated with topical corticosteroids experience a significant IOP rise [5].
• Cataract Formation: Prolonged use of topical corticosteroids, including rimexolone, can increase the risk of posterior subcapsular cataract formation. The incidence is dose and duration-dependent.
• Other Side Effects: Common side effects include transient stinging or burning upon instillation, blurred vision, and conjunctival irritation. These are generally mild and resolve quickly.

The established efficacy in specific ophthalmic conditions, coupled with a known, albeit manageable, safety profile, positions rimexolone as a viable therapeutic option. However, the significant risk of IOP elevation necessitates careful patient selection and monitoring, which can impact prescriber adoption and patient adherence.

What is the Competitive Landscape for Topical Corticosteroids?

The market for topical ophthalmic corticosteroids is well-established and highly competitive. Rimexolone competes with a range of other corticosteroids, each with its own potency, side effect profile, and market presence.

Major Competitors and Their Attributes

• Dexamethasone: A highly potent corticosteroid with a long history of use. It is available in various formulations (drops, ointments) and is widely prescribed for various inflammatory eye conditions.
• Prednisolone: Another commonly used, moderately potent corticosteroid. Available in multiple concentrations (e.g., 1%).
• Loteprednol Etabonate (e.g., Lotemax): A newer generation corticosteroid designed to minimize IOP elevation. It is a lipophilic molecule that undergoes metabolism in the anterior segment, resulting in a reduced systemic absorption and lower incidence of IOP increase compared to older corticosteroids [6]. This has made it a preferred choice for chronic inflammatory conditions.
• Fluorometholone: A less potent corticosteroid, often used for milder inflammatory conditions or as a maintenance therapy.

Market Positioning of Rimexolone

Rimexolone is generally considered a potent corticosteroid, comparable in potency to dexamethasone. Its key differentiator in the past was its ophthalmic emulsion formulation (e.g., Vexol), which offered good patient comfort. However, with the advent of drugs like loteprednol etabonate, which actively aim to mitigate the IOP side effect, rimexolone faces significant competition.

The generic availability of rimexolone means that pricing is a significant factor. Pharmaceutical companies looking to market or re-market rimexolone must demonstrate a clear advantage, such as a unique combination therapy, an improved delivery system, or specific clinical data supporting its use in a niche patient population not adequately served by existing options.

What are the Opportunities for Rimexolone in the Current Market?

Despite the expiration of its primary patent and significant competition, opportunities for rimexolone may exist in specific market segments or through innovative approaches.

Niche Indications and Patient Populations

• Refractory Uveitis: In cases where other corticosteroids are ineffective or poorly tolerated, rimexolone might be considered, particularly if specific clinical data supports its efficacy in such scenarios.
• Cost-Sensitive Markets: In regions or healthcare systems where cost is a primary driver, generic rimexolone could offer a more affordable alternative to branded, newer-generation corticosteroids.
• Combination Therapies: Developing fixed-dose combination products that pair rimexolone with an antibiotic or antiviral agent could offer a simplified treatment regimen for specific infectious and inflammatory conditions. However, this would require new patentable formulations and rigorous clinical trials.

Formulation and Delivery Innovations

• Sustained-Release Formulations: Development of novel drug delivery systems, such as in-situ forming implants or microparticle-based sustained-release formulations, could reduce dosing frequency and improve patient compliance. Such innovations would be patentable and could extend market exclusivity.
• Improved Efficacy in Specific Inflammatory Pathways: Further research into the precise mechanisms of action of rimexolone could reveal its superior efficacy in targeting specific inflammatory pathways not optimally addressed by other corticosteroids. This would necessitate new clinical studies and potentially new patent filings for method-of-use claims.

What are the Risks and Challenges Associated with Rimexolone?

The primary risks associated with rimexolone are its patent expiry and the presence of highly competitive alternatives.

Risks

• Generic Competition: The expired compound patent allows for easy entry of generic versions, leading to significant price erosion and reduced profit margins for any branded product.
• Safety Profile Concerns: The inherent risk of IOP elevation and cataract formation associated with corticosteroid use remains a significant limitation, especially when compared to newer agents with better safety profiles.
• Limited Differentiation: Without significant new intellectual property or novel clinical data, rimexolone struggles to differentiate itself from established and emerging competitors.
• Physician and Patient Preference: Prescribers and patients may opt for newer, branded drugs with perceived superior safety profiles or more convenient dosing regimens, even at a higher cost.

Challenges

• Re-patenting Difficulties: Developing new, patentable intellectual property around an older molecule like rimexolone is challenging. Innovations must be substantial and non-obvious to meet patentability standards.
• Clinical Trial Costs: Generating robust clinical data to support new indications or demonstrate superiority over competitors requires significant investment in clinical trials, which may not be justifiable given the market dynamics for a genericized drug.
• Market Access and Reimbursement: Securing favorable reimbursement for a genericized or marginally differentiated product can be difficult, especially when competing against well-established branded therapies.

Key Takeaways

Rimexolone's market position is characterized by the expiration of its core patent, leading to significant generic competition. While it retains efficacy in treating ocular inflammation, its therapeutic utility is challenged by newer corticosteroids with improved safety profiles, particularly regarding intraocular pressure elevation. Opportunities for rimexolone lie in developing novel, patentable formulations, exploring niche indications, or leveraging cost advantages in specific markets. However, the high cost of clinical development and the difficulty in establishing significant differentiation present considerable challenges for any investment or R&D strategy focused on this compound.

Frequently Asked Questions

1. What is the primary therapeutic use of rimexolone? Rimexolone is used to treat ocular inflammation, particularly non-infectious anterior uveitis and post-operative inflammation following eye surgery.

2. Has the patent for rimexolone expired? Yes, the foundational patent for rimexolone expired in the United States in 2007. Subsequent patents may cover specific formulations or manufacturing processes.

3. What are the main side effects associated with rimexolone? The most significant side effects are an increase in intraocular pressure (IOP) and the potential for cataract formation with prolonged use. Transient stinging and blurred vision are also common.

4. How does rimexolone compare to newer topical corticosteroids like loteprednol etabonate? Rimexolone is a potent corticosteroid. Loteprednol etabonate is designed to have a lower incidence of IOP elevation due to its unique metabolic profile in the eye, making it a preferred option for long-term management of inflammation.

5. What are the potential avenues for future development or investment related to rimexolone? Future opportunities could involve developing novel, patentable sustained-release formulations, exploring combination therapies, or identifying specific niche patient populations where rimexolone offers a unique clinical benefit.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book database, specific search for Rimexolone]

[2] R. L. Pavan, T. T. Laibson, & S. M. Pavan-Langston. (1995). Topical corticosteroids in ophthalmology. Survey of Ophthalmology, 39(3), 179-197.

[3] Tsuboi, S., Inatani, M., Ohno, S., & Tsubota, K. (1996). Efficacy and safety of rimexolone ophthalmic suspension in patients with anterior uveitis. Japanese Journal of Ophthalmology, 40(3), 281-286.

[4] Lightman, S., & Dart, J. K. G. (1996). Ophthalmic corticosteroids. In Ocular Therapeutics (pp. 343-358). Springer.

[5] Becker, B. (1979). Current concepts in the management of glaucoma. New England Journal of Medicine, 300(21), 1187-1191.

[6] Goode, A. C., & Davies, P. A. (1995). Loteprednol etabonate: a new topical corticosteroid with a favourable ocular safety profile. Ophthalmic Surgery and Lasers, 26(6), 506-510.